Evaluating the Efficacy Vardenafil 10 mg vs Tadalafil 10 mg in in Subjects With Erectile Dysfunction (ED) - Full Text View

Sponsor:	Bayer
Collaborator:	GlaxoSmithKline
Information provided by:	Bayer
ClinicalTrials.gov Identifier:	NCT00663130

Purpose

Evaluating the efficacy of 10mg vardenafil versus 10mg tadalafil in the first 45 minutes post-dosing, in an as-required regimen for 4 weeks in subjects with mild/moderate to severe ED

Condition	Intervention	Phase
Erectile Dysfunction	Drug: Levitra (Vardenafil, BAY38-9456) Drug: Tadalafil	Phase IV

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Active-Controlled Study Evaluating the Efficacy of Vardenafil Versus Tadalafil When Intercourse is Attempted Within 45 Minutes of Administration in Subjects With Erectile Dysfunction

Resource links provided by NLM:

MedlinePlus related topics: Erectile Dysfunction

Drug Information available for: Tadalafil Vardenafil

U.S. FDA Resources

Further study details as provided by Bayer:

Primary Outcome Measures:

Sexual Encounter Profile Question 3 (SEP-3) [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Sexual Encounter Profile Question 2 (SEP-2) [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
International Index of Erectile Function [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
Global Confidence Question (GCQ) [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
Erection Quality Scale (EQS) [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
General Safety [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]

Enrollment:	759
Study Start Date:	April 2004
Study Completion Date:	July 2004

Arms	Assigned Interventions
Arm 1: Experimental	Drug: Levitra (Vardenafil, BAY38-9456) Vardenafil 10mg, taken orally within 1 hour prior to sexual intercourse
Arm 2: Active Comparator	Drug: Tadalafil Tadalafil 10mg, taken orally within 1 hour prior to sexual intercourse

Eligibility

Ages Eligible for Study:	18 Years to 64 Years
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Age between 18 and 64 years
Heterosexual males
Erectile dysfunction for more than 6 months

Exclusion Criteria:

Penile anatomical abnormalities
Spinal cord injury
History of surgical prostatectomy

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00663130

Sponsors and Collaborators

Bayer

GlaxoSmithKline

Investigators

Study Director:

Bayer Study Director

Bayer

More Information

Additional Information:

Click here to find results for studies related to marketed products This link exits the ClinicalTrials.gov site

Click here and search for drug information provided by the FDA This link exits the ClinicalTrials.gov site

Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Bayer Healthcare AG ( Medical Affairs Therapeutic Area Head )
Study ID Numbers:	11333
Study First Received:	April 17, 2008
Last Updated:	June 29, 2009
ClinicalTrials.gov Identifier:	NCT00663130 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Bayer:

Erectile Dysfunction
Vardenafil

Additional relevant MeSH terms:

Sexual Dysfunctions, Psychological
Phosphodiesterase Inhibitors
Vardenafil
Sexual Dysfunction, Physiological
Molecular Mechanisms of Pharmacological Action
Mental Disorders

Tadalafil
Enzyme Inhibitors
Genital Diseases, Male
Sexual and Gender Disorders
Erectile Dysfunction
Pharmacologic Actions

ClinicalTrials.gov processed this record on February 08, 2010